KDR and neoplasm: More vaccines and immunization strategies have been developed and tested in pre-clinical models against VEGF/VEGFR2 than with any other tumor angiogenic marker [43,45,58-67], and as a result, VEGF and VEGFR2 targeting will be described separately.